Bioconjugated solid lipid nanoparticles (SLNs) for targeted prostate cancer therapy

Akanda, Mushfiq; Getti, Giulia; Nandi, Uttom; Mithu, Sadeque Hossain; Douroumis, Dennis

doi:10.1016/j.ijpharm.2021.120416

Cited by 42 publications

(16 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When everything is considered together, it is anticipated that TPGS engineered nanoscale lipid-based LDDS will increase the therapeutic outcomes of ST in the treatment of Colorectal cancer ( 59 ). Similar results were previously reported in Mushfiq Akanda et al ( 60 ) work, where the researcher reported 50 µg/mL Tf-CRC-SLN exhibited significant increase in late apoptotic/early necrotic cell population only (p<0.05) compared to the curcumin (CRC)loaded SLN during formulation development and in vivo studies on prostate cancer through bio conjugated solid lipid nanoparticles ( 60 ). In a similar vein, Han Li et al.…”

Section: Resultssupporting

confidence: 89%

“…When everything is considered together, it is anticipated that TPGS engineered nanoscale lipid-based LDDS will increase the therapeutic outcomes of ST in the treatment of Colorectal cancer (59). Similar results were previously reported in Mushfiq Akanda et al loaded SLN during formulation development and in vivo studies on prostate cancer through bio conjugated solid lipid nanoparticles (60). In a similar vein, Han article suggests that the combination of sorafenib and ursolic acid may involve the induction of Mcl-1-related apoptosis and SLC7A11-dependent ferroptosis (61).…”

Section: Apoptotic Studysupporting

confidence: 74%

See 1 more Smart Citation

Development of D-α-Tocopherol polyethylene glycol 1000 succinate fabricated nanostructural lipid carrier of sorafenib tosylate for metastatic colorectal targeting application: Stability, physical characterization, cytotoxicity, and apoptotic studies against SW48 cells PTEN

2022

View full text Add to dashboard Cite

The study aimed to create D-α-Tocopherol polyethylene glycol 1000 succinate (TPGS) nanostructured lipid carriers (NLC) of sorafenib tosylate (ST) as lymphatic delivery systems (LDDS) to fight Metastatic colorectal cancer. Initially, ST-SLN, ST-NLC, and ST-LNE were formulated considering oleic acid (OA), glycerol monolinoleate (GMO), glycerol monolinoleate (GML) as solid lipid and further characterised, and tested for stability. The most stable ST-NLC was fabricated with TPGS to produce ST-TPGS-NLC and evaluated by performing in vitro drug profiling, in vitro cytotoxicity, and apoptotic studies against human female colorectal adenocarcinoma cell lines (SW48 Cells PTEN). Stability studies on three lipidic nanoparticles (ST-SLN, ST-NLC, ST-LEN) showed particle size, polydispersity index, and zeta potential ranging from 165 nm to 298 nm, 0.125 to 0.288, and -31 mV to -16 mV. At 1600 minutes, more than 80% of ST-NLC1 was released, confirming the sustained release pattern of the formulation. ST-NLC and ST-TPGS-NLC have entrapment efficiencies above 50%. Pure ST’s IC50 at 72 hr was 3.45 µg/mL, while 1.56 µg/mL was for ST-TPGS-NLC. The ST-TPGS-NLC reduced the number of livings SW48 Cells PTEN from 91% to 5%, compared to 75% to 8% of pure ST. The ST-TPGS-NLC is a promising LDDS for delivering ST for metastatic colorectal cancer.

show abstract

Section: Resultssupporting

confidence: 89%

“…When everything is considered together, it is anticipated that TPGS engineered nanoscale lipid-based LDDS will increase the therapeutic outcomes of ST in the treatment of Colorectal cancer (59). Similar results were previously reported in Mushfiq Akanda et al loaded SLN during formulation development and in vivo studies on prostate cancer through bio conjugated solid lipid nanoparticles (60). In a similar vein, Han article suggests that the combination of sorafenib and ursolic acid may involve the induction of Mcl-1-related apoptosis and SLC7A11-dependent ferroptosis (61).…”

Section: Apoptotic Studysupporting

confidence: 74%

Development of D-α-Tocopherol polyethylene glycol 1000 succinate fabricated nanostructural lipid carrier of sorafenib tosylate for metastatic colorectal targeting application: Stability, physical characterization, cytotoxicity, and apoptotic studies against SW48 cells PTEN

2022

View full text Add to dashboard Cite

show abstract

“…Jain et al recently created transferrin (Tf)-conjugated SLNs (Tf-SLNs) and tested them for temozolomide (TMZ) transport to the brain for GBM treatment. The intensity of fluorescence seen in cellular uptake studies was higher in Tf receptor-targeted SLNs than in non-targeted SLNs [ 148 ]. Martins et al investigated the capacity of camptothecin-loaded SLNs to enter the brain parenchyma after passing through the BBB in another investigation.…”

Section: Formulation-based Approachesmentioning

confidence: 99%

Involvement of Resveratrol against Brain Cancer: A Combination Strategy with a Pharmaceutical Approach

et al. 2022

View full text Add to dashboard Cite

A brain tumor (BT) is a condition in which there is growth or uncontrolled development of the brain cells, which usually goes unrecognized or is diagnosed at the later stages. Since the mechanism behind BT is not clear, and the various physiological conditions are difficult to diagnose, the success rate of BT is not very high. This is the central issue faced during drug development and clinical trials with almost all types of neurodegenerative disorders. In the first part of this review, we focus on the concept of brain tumors, their barriers, and the types of delivery possible to target the brain cells. Although various treatment methods are available, they all have side effects or toxic effects. Hence, in the second part, a correlation was made between the use of resveratrol, a potent antioxidant, and its advantages for brain diseases. The relationship between brain disease and the blood–brain barrier, multi-drug resistance, and the use of nanomedicine for treating brain disorders is also mentioned. In short, a hypothetical concept is given with a background investigation into the use of combination therapy with resveratrol as an active ingredient, the possible drug delivery, and its formulation-based approach.

show abstract

“…Several types of nanoparticles have been used in the diagnosis and therapy of cancer such as inorganic nanoparticles [13][14][15], solid lipid nanoparticles [16,17], and polymeric nanoparticles [18][19][20]. Among the investments in nanotechnology, inorganic nanoparticles have received special attention for their use as diagnostic and therapeutic agents [21][22][23].…”

Section: Introductionmentioning

confidence: 99%

The Selective Inhibitory Effect of Silver Nitroprusside Nanoparticles on Breast Tumor Growth

Fernandes

Jayme

Matsuo

et al. 2022

Preprint

View full text Add to dashboard Cite

A number of different metallic nanoparticles have been extensively investigated in recent years based on their diverse potential in biomedical and cancer applications, antibacterial activity, and chemical properties. Here, silver nitroprusside nanoparticles (AgNPs) were prepared from silver nitrate and sodium nitroprusside, and their anticancer activity was evaluated. AgNPs were prepared and characterized by Fourier transform infrared (FTIR), X-ray diffraction (DRX), scanning electron microscopy (SEM), X-ray dispersive energy spectroscopy (EDX), and transmission electron microscopy (TEM). In vitro tests were performed using two breast cancer cell lines, including a non-malignant breast epithelial cell line (MCF-10A) and a breast cancer cell line (MCF-7). The results obtained through cytotoxicity assays (MTT and resazurin) and bright-field microscopy revealed that AgNPs (3.0 mg/mL) exhibited specific selectivity for non-malignant breast epithelial cells. They were toxic to tumorigenic cells (MCF-7) with a lower selective toxicity to non-malignant breast epithelial cells (MCF-10A). In vivo imaging system (IVIS) imaging demonstrated the antitumor activity of AgNPs (3.0 mg/mL) compared to that of the control, and this was confirmed through histological analysis without any potential systemic toxicity. These results suggest that AgNPs possess potential anticancer applications in breast cancer treatment.

show abstract

Bioconjugated solid lipid nanoparticles (SLNs) for targeted prostate cancer therapy

Cited by 42 publications

References 35 publications

Development of D-α-Tocopherol polyethylene glycol 1000 succinate fabricated nanostructural lipid carrier of sorafenib tosylate for metastatic colorectal targeting application: Stability, physical characterization, cytotoxicity, and apoptotic studies against SW48 cells PTEN

Development of D-α-Tocopherol polyethylene glycol 1000 succinate fabricated nanostructural lipid carrier of sorafenib tosylate for metastatic colorectal targeting application: Stability, physical characterization, cytotoxicity, and apoptotic studies against SW48 cells PTEN

Involvement of Resveratrol against Brain Cancer: A Combination Strategy with a Pharmaceutical Approach

The Selective Inhibitory Effect of Silver Nitroprusside Nanoparticles on Breast Tumor Growth

Contact Info

Product

Resources

About